US FDA’s ODAC Pushes Back Against ‘Leading’ Questions

 
• By Michael McCaughan
  
question
Did the FDA push ODAC too much with its voting question on Pepaxto? • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers